KRAS-driven MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway, which might provide a mechanistic rationale for the use of a MEK inhibitor as an adjuvant, in combination with standard of care, to prevent the recurrence of CRLM in KRAS mutant CRC patients after receiving liver resection, however, further investigation is needed. This evidence concerns the gene KRAS and colorectal carcinoma.